“NIH Clinical Trial of Investigational Vaccine for COVID-19 Begins.” 2020. NIH: National Institute of Allergy and Infectious Diseases. March 16, 2020. www.niaid.nih.gov/news-events/nih-clinical-trial-investigational-vaccine-covid-19-begins. Abstract: A Phase 1 clinical trial evaluating an investigational vaccine designed to protect against coronavirus disease 2019 (COVID-19) has begun at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is funding the trial. KPWHRI is part of NIAID’s Infectious Diseases Clinical Research Consortium.
The [National Institute of Allergy and Infectious Diseases (NIAID)](www.niaid.nih.gov/diseases-conditions/coronaviruses), part of the National Institutes of Health, is funding the trial.
The vaccine is called mRNA-1273 and was developed by NIAID scientists and their collaborators at the biotechnology company Moderna, Inc., based in Cambridge, Massachusetts. The Coalition for Epidemic Preparedness Innovations (CEPI) supported the manufacturing of the vaccine candidate for the Phase 1 clinical trial.
“Finding a safe and effective vaccine to prevent infection with SARS-CoV-2 is an urgent public health priority,” said NIAID Director Anthony S. Fauci, M.D. “This Phase 1 study, launched in record speed, is an important first step toward achieving that goal.”